ALERT Communities Act
ALERT Communities Act
Plain Language Summary
# ALERT Communities Act Summary **What It Does** The ALERT Communities Act would expand federal grant programs to help first responders and communities detect dangerous drugs like fentanyl and xylazine using rapid test strips. Currently, the government funds grants for overdose treatment equipment; this bill adds funding for test strips that can quickly identify whether drugs contain these substances.
The bill also directs the Department of Health and Human Services to create guidelines for companies developing these test strips and to study their effectiveness. **Who It Affects** The bill primarily affects first responders (police, paramedics, firefighters), public health agencies, and community organizations that work on opioid overdose prevention. It could indirectly benefit people struggling with substance use disorders and their communities by providing tools to identify contaminated drugs and prevent overdose deaths. **Current Status** The bill (HR 1561) was introduced in the 119th Congress by Representative Jasmine Crockett (D-Texas) and is currently in committee, meaning it has not yet been voted on by the full House of Representatives.
CRS Official Summary
Advancing Lifesaving Efforts with Rapid Test strips for Communities Act or the ALERT Communities ActThis bill establishes programs and requirements to advance the development and usage of test strips that detect the presence of certain hazardous drugs (e.g., fentanyl, xylazine). Currently, the Substance Abuse and Mental Health Services Administration provides grants to government entities to train and provide authorized equipment to first responders and other relevant personnel for emergency treatment of opioid overdoses. The bill expands these grants to include rapid response test strips for detecting the presence of fentanyl, xylazine, and other synthetic opioids or emerging substances in people or within other drugs.Additionally, the bill requires the Department of Health and Human Services (HHS) to publish guidance and standards for test strip manufacturers to support the development, evaluation, and authorization of test strips.Also, HHS must conduct a study and report to Congress on how the availability and usage of test strips and similar equipment impacts the frequency of overdoses and participation in substance use disorder treatment.
Latest Action
Referred to the House Committee on Energy and Commerce.